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Executive Summary 
Recently,  drug-eluting  stents  have  become  a  common  treatment  for  coronary  heart  disease.  
These stents are usually loaded with a drug that prevents restenosis.  Unfortunately, there are 
risks associated with the placement of these metallic structures in the body.  Stent thrombosis is 
one  such  problem,  and  can  lead  to  restenosis  despite  the  presence  of  drug.    Advances  in 
biomaterials have led to the development of biodegradable stents, which can reduce the risks 
associated with stents.  However, since it is a relatively new technology, it is not known to what 
degree  the  biodegradability  affects  the  drug  releasing  properties  of  the  stent.    We  hope  to 
characterize these effects and to determine if the biodegradability reduces the efficacy of the 
stent when compared to normal non-degradable stents.  To accomplish this, we modeled a stent 
that  diminished  in  size  over  time  using  COMSOL  Multiphysics,  and  monitored  the  drug 
concentration in the nearby tissue.  We established that our model was a viable predictor of 
actual stent behavior by comparing our simulated results with previous studies.  We were then 
able to determine the optimal initial loading stent concentration of our modeled drug, paclitaxel, 
to ensure therapeutic levels in the tissue.  Lastly, we found that drug concentrations in the tissue 
were  not  substantially  different  between  the  degradable  and  non-degradable  models.    This 
affirms the effectiveness of using biodegradable stents, showing them as a viable alternative to 
traditional metal stents. 
Introduction 
With  the  advent  of  the  balloon  angioplasty  technique  stents  have  become  one  of  the  major 
methods  of  treating  obstructive  coronary  artery  disease  over  the  past  decade.    While  this 
procedure is effective in alleviating symptoms of ischemic coronary artery disease, it can also 
hinder  surgical  revascularization;  effectively  blocks  vessel  side  branches,  prevents  positive 
remodeling,  requires  long-term  anti-platelet  therapy,  and  predisposes  the  vessel  to  late  stent 
thrombosis. Page | 3  
 
Advances in biomaterials have led to the development of biodegradable stents.  Polymers such as 
poly(d,l-lactic acid) (P(DL)LA) and poly(d,l-lactic-co-glycolic acid) (P(DL)LGA) can be used to 
construct stents which can be broken down in the body over a relatively short period of time.  
This is particularly important in cardiology for several reasons.  Considering the short-term need 
and the long-term complications with metallic stents, biodegradable drug-eluting stents may be a 
suitable alternative.  These types of stents are completely broken down in the body, thereby 
eliminating  the  potential  complications  of  arterial  rupture,  intimal  hyperplasia,  and 
thrombogenesis.  More importantly, the risk of stent restenosis can be decreased by paclitaxel-
eluting coronary stents, which significantly reduce neointimal hyperplasia after stent placement, 
resulting in increased vessel diameter, and reduced restenosis. 
Paclitaxel  is  an  antiproliferative  compound  that  binds  to  tubulin  and  so  inhibits  the  regular 
separation of chromosomes in dividing cells.  Past research has shown that the use of paclitaxel-
eluting stents has contributed to better healing and effective inhibition of restenosis.  However, 
the stent must not degrade either too early or too late because a therapeutic concentration of the 
drug is desired in the tissue to inhibit restenosis.  For this reason, the timing of the optimal 
degradation period must be taken into consideration.  However, since drug-eluting stents are a 
relatively new technology, little research has been conducted characterizing these stents and their 
effects in the body. 
Design Objectives 
The goal of our project is to determine the drug release mechanism and the drug concentration 
profiles from P(DL)LA, P(DL)LGA stent-based delivery of paclitaxel in arterial tissue. Thus, we 
first needed to design a model which could accurately predict paclitaxel release behavior for both 
degradable and non-degradable stents. This would require obtaining information on the various 
geometries and physical parameters of the stent and drug. Page | 4  
 
We then hoped to determine the optimum initial loading of the stent, such that the concentration 
of paclitaxel in the tissue would remain within therapeutic bounds for the duration of the stent’s 
presence in the body, a period of about thirty-two days. This is essential because paclitaxel at too 
high a concentration can cause cytotoxic effects in the tissue. However, it is also necessary for 
the drug to remain above a certain level in order to ensure proper prevention of restenosis.  
Lastly, we wished to confirm the viability of biodegradable stents for treating coronary artery 
disease. Since this is a relatively new technology, it is necessary to ensure that they maintain the 
same level of efficacy as the more traditional metal stent treatment. The effects of the receding 
stent edges will alter the distribution of drug in the tissue. However, we hope to show that the 
concentration of paclitaxel in the arterial wall does not differ significantly from that of metal 
stents. 
Schematic 
The  model  assumes  that  the  drug  diffusion  occurs  at  the  following  three  regions,  the  PLA 
polymer, the drug-loaded PLGA polymer, and the arterial tissue. A 2D axis-symmetric model 
about the center of the lumen was used to represent the implanted stent. The stent was assumed 
to be non-slipping and directly in contact with the tissue.  We modeled the stent as a thin slab in 
contact with a large segment of arterial tissue.  The stent is composed of two layers: a thicker 
insulating containing no drug initially, and a thin layer in between the first layer and the tissue, 
which  is  loaded  with  drug.    These  two  layers  degrade  from  their  thin  ends  at  a  fixed  rate. 
 
Figure  1:  Schematic  of  COMSOL  model.    (a) 
Relatively  low-diffusivity  polymer  P(DL)LA  to 
minimize diffusion in the r direction.  (b) Drug-
loaded polymer, P(DL)LGA.  (c) Arterial tissue.  
Governing equation Figure not drawn to scale. 
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Some  simplifications  to  our  model  had  to  be  incorporated  so  that  it  could  be  effectively 
implemented in COMSOL.  We found literature values on the solubility of paclitaxel in water, 
which was found to be very small.  We therefore assumed that the solubility in plasma was also 
negligible, which allowed us to disregard mass transfer into the blood.  The degradation rate and 
manner we also simplified; real stents do not degrade in a linear fashion and usually develop 
pores rather than degrading along a single axis.  Lastly, we assumed the pharmacokinetics of 
paclitaxel to be first-order kinetics.  This is a reasonable approximation from data we found from 
previous studies. 
Results and Discussion 
Initial Load 
We  used  the  drug  concentration  from  Venkatasubramanian  (2008)  as  the  paclitaxel  drug 
concentration  in  the  stent  (69.30  µM).    With  our  model,  we  noted  a  sharp  rise  in  tissue 
concentration within the first 10 hours.  At the initial load used by Venkatasubramanian, we 
found that the spike in drug concentration (see Figure 11) in the tissue would be above the 
therapeutic maximum of 10,000 nM.  The concentration used in their research was to treat cancer 
tissue where toxicity was less of a concern; we on the other hand are attempting to determine a 
concentration suitable for healthy tissue.  We then reduced the initial load in our stent to 60% of 
the value used by Venkatasubramanian in 10% increments. 
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Figure 2: Concentration at center, 5 microns 
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It  was  determined  that  at  80%  the  peak  concentration  would  be  below  toxic  levels  while 
maintaining the highest therapeutic concentration at  day  32  (Figure 12).  At this  load, drug 
concentration in the tissue 5 µm from the stent would peak at 9,596 nM. 
Tissue Concentration 
As expected, there is a higher concentration of paclitaxel near where the stent was implanted.  
The  region  of  the  coronary  artery  that  has  a  drug  concentration  higher  than  the  minimum 
concentration (100 nM) is indicated by the red and green areas.  The line shows where the 
concentration is 100 nM. 
 
Figure 3: Surface plot of final paclitaxel concentration (after 32 days).  Line indicates 100 nM. Page | 7  
 
It is clear that the region immediately surrounding the stent contains a therapeutic concentration 
of the drug, thus we can assume that there is a low likelihood of restenois, since the area with the 
highest probability of blockage (near the stent) is also the area with the highest concentration of 
the drug.  Particularly the fact that the drug persists in the tissue after the stent has degraded is a 
marked improvement over drug coated metal stents. 
Moving versus Nonmoving Models 
After determining the optimum initial load of our stent, we compared our moving model of the 
biodegradable stent (degradation) with a modified nonmoving model (no degradation) to see if 
the degradation of the biodegradable stent causes any significant changes in drug concentration 
in  tissue  as  compared  to  a  traditional  non-degrading  stent.    We  chose  a  point  at  z=11mm, 
r=1.85mm (1 mm from the end of the original stent length, and 0.2mm depth into the tissue) 
because we reasoned that differences in drug concentration would be most visible in tissue nearer 
the  edge  of  the  stent.    In  this  area,  the  shortening  of  the  stent  may  result  in  lowered  drug 
concentration. 
 
Figure 4: Comparison of concentration at a single point between non-moving and moving model. Page | 8  
 
After running both models and comparing the drug concentration over time at our chosen point, 
we see that the moving model has a very similar concentration profile as the non-moving model 
(Fig. 5).  We recognize that the drug concentration is slightly lower in the moving model than in 
the nonmoving model, but the difference is not apparent until about 5 days after initial time.  The 
concentration from the moving model remains similar to that of the nonmoving model, and both 
models stay well above the minimum therapeutic concentration of 100nM and under the toxicity 
limit  of 10,000 nM  throughout  the duration of the simulation.   Thus,  we conclude that  our 
moving  model,  representing  a  biodegradable  stent,  is  as  effective  as  the  nonmoving  model, 
representing a non-degrading stent, in delivering appropriate concentrations of paclitaxel into the 
tissue.  
Validation 
To validate the release profile of our model over time, we examined the experiment reported by 
Levin et al. in 2004 in which the authors investigated the release profile of paclitaxel into calf 
internal carotid arteries over a period of 72 hours by measuring the total concentration present in 
the tissue at different times.  The authors presented the release profile as a normalized drug 
concentration, a fraction of the final drug concentration.  We used our model and modified the 
tissue diffusivity and initial load to those reported in the study to simulate their experiment 
conditions and compared the results. 
 
  Figure 5: Comparison of Paclitaxel release from previous experimental data (left, Levin et al. 2004) and our simulation 
(right)  
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We observed that the release curve we obtained is very similar to that from the study. Our 
simulation underestimates the amount of drug released in the first day, but closely corresponds to 
the release profile in the second and third days of the experiment. We feel that this comparison 
validates the release profile of paclitaxel over time as simulated in our model.  
  
Figure 6: paclitaxel drug concentration in tissue normalized to initial stent concentration from our model (right) and 
previous experimental data (left, Creel 2000). 
We adjusted our model to the geometry used in a previous experiment which used calf carotid 
arteries  (Creel  et  al.,  2000),  and  found  that  our  model  closely  mimics  their  measured 
experimental values (Fig. 8).  We used a drug diffusivity of 2.91·10
-13 m
2/s with an initial stent 
load of 0.017 mg/L and observed our results after 15 minutes.  Looking at the concentration 
gradient, we see the same results as the authors in their endovascular drug delivery experiment.  
The profile at later times were not evaluated since the experiment done by Creel was such that 
the  tissue  diffusivity  varied  as  the  experiment  changed  over  time  due  to  steric  hindrance, 
nonspecific binding, and an experimentally imposed pressure gradient. 
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Sensitivity Analysis 
We evaluated the concentration in the tissue at the center of the stent, at a point 0.2 mm within 
the  arterial  tissue  (r=.00185,  z=.006  for  the  field  values  in  COMSOL).  We  analyzed  three 
parameters of our model; drug diffusivity in the tissue and stent, and drug degradation in the 
tissue.  Since our model changed over time, we wanted to assess both the short and long-term 
effects of varying these parameters on our results (Figure 9). 
 
Figure 7: Sensitivity analysis at day 2.5. 
 
Figure 8: Sensitivity analysis at day 12. 
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We found that stent diffusivity had little effect on the resulting concentration at both days 2.5 
and 12.  However, both tissue diffusivity and degradation rate exhibited a similar magnitude of 
sensitivity.    This  sensitivity  for  both  parameters  was  also  slightly  greater  at  twelve  days  as 
opposed  to  the  2.5-day  condition.    It  is  interesting  to  note  that  increasing  tissue  diffusivity 
produced a higher concentration on day 2.5, while lowering concentration on day 12, and vice 
versa.  Altering tissue degradation produced the same trend for both time points. As drug is 
initially entering the tissue, a higher diffusivity facilitates movement from stent into the arterial 
wall.  However, at the later time point, most of the drug has already been transferred out of the 
stent.    Thus,  the  higher  diffusivity  makes  it  easier  for  drug  to  leave  the  region  near  the 
stent/tissue interface (the location of the test point) and move deeper into the tissue. 
Conclusion 
Results  indicate  that  the  proposed  biodegradable  stent  model  is  effective  in  delivering  a 
therapeutic level of Paclitaxel to tissue surrounding the coronary artery.  By implementing our 
parameters, boundary conditions, and initial conditions, the model displays stent degradation at 
the  ends  in  the  z-direction  (up  and  down)  and  successful  transport  of  the  drug  into  tissue.  
Concentration  of  Paclitaxel  in  this  region  next  to  the  stent  is  greater  than  the  minimum 
therapeutic value.  In order to validate our model two past experiments that focused on Paclitaxel 
drug elution from a stent was looked at.  First, a calf coronary artery was compared to our model.  
Implementing Creel’s experimental parameters, our model was able to show a Paclitaxel release 
profile from the stent and tissue interface to .14mm in the tissue layer after 15 minutes.  Our 
release profile closely resembles Creel’s.  Hence, our model is supported by this literature as it 
delivers a realistic drug concentration within tissue.  Second, a calf carotid artery was compared 
to  our  model.    Utilizing  Levin’s  experimental  parameters,  our  model  was  able  to  show  a 
Paclitaxel 72 hour release profile.  Besides the initial underestimation of the drug concentration 
for first 24 hours, our model closely mimics Levin’s experimental results. This supports the 
usefulness of our time-release profile and our model. Page | 12  
 
Our  model  showed  that  the  literature  initial  tissue  Paclitaxel  concentration  beyond  the 
therapeutic concentration range as it was over 10,000 nM.  After using different fractions of this 
initial  concentration,  the  most  effective  therapeutic  concentration  was  found  to  be  80%  of 
literature value.  Results indicate that this initial concentration produces a release profile with 
concentrations that stay in therapeutic range through at least 32 days.  This initial concentration 
of Paclitaxel ensures therapeutic delivery of the drug. 
Simulation with both of our stent models biodegradable and non-biodegradable showed similar 
Paclitaxel concentration profiles. Besides the slightly lower concentrations from day 5 to day 32, 
the biodegradable model, which moves or degrades at the ends, is nearly identical to the non-
biodegradable model. 
By  comparing  our  model  with  past  experiments  and  showing  that  our  model  degrades  and 
delivers drug at an appropriate level, a simple biodegradable stent model has been developed. 
However,  more  research  that  supports  our  assumptions  or  takes  into  account  more  specific 
details  of  a  biodegradable  stent  must  be  conducted  in  order  to  further  validate  our  model. 
Assumptions including low drug solubility in blood plasma, linear stent degradation, and first 
order drug kinetics can be addressed in future models. By including solubility of drug in blood 
plasma a convective term in the mass transfer can be added to represent blood flow that removes 
the drug from the stent polymer layers.  Stent degradation occurs through pores within the stent 
and  is  at  an  exponential  rate.    Complex  drug  kinetics  is  generally  higher  than  first  order. 
Accounting for these realistic scenarios and parameters that are more accurate, a more effective 
biodegradable stent model can be developed. 
This loss in concentration due to rapid early stent biodegradation may be taken into account in 
the future stent design.  Overcoming these losses may allow for a lower initial concentration and 
a more therapeutically effective drug release into the tissue.  The obtained drug release profile 
seemed to simulate real-life Paclitaxel release in tissue when compared with established release 
profiles.  However, due differences in models of release (in vivo or in vitro), species’ tissue type, 
and  parameters  such  as  diffusivities  more  research  accounting  these  variations  must  be 
conducted  to  confirm  our  results.    The  sensitivity  analysis  showed  that  variation  in  tissue 
diffusivity can change concentration levels, and should be a main concern for stent design. A Page | 13  
 
higher or lower initial drug concentration in the stent may be needed depending on the diffusivity 
of the tissue.  Research taking into account these types of variations may prove helpful in future 
biodegradative drug releasing stent models.  
Design Recommendations 
Regarding  the  health  safety  hazards  of  the  biodegradable  stent,  there  are  areas  of  concern 
including  Paclitaxel  toxic  concentration  and  side  effects.    Research  has  shown  that  adverse 
events have occurred with Paclitaxel stents including subacute and late thrombosis, aneurysm 
formation  and  hypersensitivity  reactions  in  humans.    Paclitaxel  may  cause  hypersensitivity 
reactions due to the interaction between these elements in the body through natural metabolic 
reactions such as hydrolysis.  These problems should be our main areas of concern, therefore, our 
contribution to ongoing research and development for an improved model is greatly needed. 
Due to the complexity of the human body the manufacturability of PLA, PLGA polymer stents 
seems  to  be  challenging.    There  are  existing  synthesized  PLA,  PLGA  drug  loaded  stents, 
however their specifications and requirements have not been thoroughly evaluated.  Problems 
including incompatibility due to poor polymer quality or processing (residual solvents, catalysts, 
and  monomers),  inflammatory  degradation  residues,  inefficient  viscoelastic  and  mechanical 
properties, and inadequate drug release profile are all barriers to stent manufacturing.  These 
biodegradable stents do not have metal stent struts.  Therefore, the mechanical support structure 
of stent has to be designed accordingly to compensate, and the more delicate polymers require 
tighter manufacturing control to ensure proper fabrication with sound structural composition.  
Our model has shown the potential efficacy of the stent, however these other specifications must 
be met before any fabrication can take place. Page | 14  
 
Appendix A 
Governing Equation 
Mass transfer equation with transient, diffusion and generation terms. 
 
Boundary Conditions 
All boundary conditions are set to have zero flux. 
 
We justify the zero flux boundary conditions for the tissue by modeling the tissue as significantly 
larger in size than the stent. Effects at these far off boundaries are thus deemed negligible. The 
zero  flux  condition  of  the  P(DL)LA  layer  is  justified  because  it  has  been  established  that 
paclitaxel solubility in water is very low, about 0.3513 uM. Since blood plasma is largely water, 
these effects negligible and the zero flux condition is established for this polymer layer. 
Initial Conditions 
cP(DL)LA = ctissue = 0 
cP(DL)LGA =   (Venkatasubramanian 2008) 
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Physical Parameters 
Table 1: Physical parameters used. 
Parameter  Value  Source 
P(DL)LA thickness  120 µm  Lao, 2007 
P(DL)LGA thickness  30 µm  Lao, 2007 
Stent Length  12 mm  Tamai,  2000 
Coronary artery (inner) radius  1.5 mm  Kaimkhani, 2004 
Coronary artery thickness  1.9 mm  Gradus-Pizlo, 2003 
Tissue diffusivity  1.1x10
-13 m
2/s  Venkatasubramanian, 2008 
P(DL)LGA diffusivity  5.7x10
-13 m
2/s  Alexis, 2004 
P(DL)LA diffusivity  4.9x10
-16 m
2/s  Alexis, 2004 
Stent Degradation Velocity  2.1724537x10
-9 m/s  Lao, 2008 
Length of time of interest  32 days  Lao, 2008; Alexis, 2004 
Paclitaxel half life in tissue  17000 minutes  Fung, 1998 
Paclitaxel degradation coefficient  -6.79556059x10
-7 mol/(m
3s)  Calculated from Fung, 1998 
Paclitaxel cytotoxic threshold  10,000 nM  Bennett, 2003 
Paclitaxel Therapeutic Range  100 nM – 10,000 nM  Sheikh, 2000 
 
The  degradation  coefficient  was  calculated  assuming  a  degradation  model  of  the  form 
with the differential form  and solving for the coefficient of t using the half life 
from literature. 
Appendix B 
Implementation 
We implemented the stent degradation by approximating the degradation rate as linear.  By using 
degradation rates determined by Fung (1998), we calculated the time it would take for the stent 
to be reduced to 4% of its initial mass.  We linearized this rate and modeled the sent as a moving 
mesh within COMSOL with mass loss occurring at the both ends of the stent (in the z-axis), with 
the presence of the P(DL)LA layer to act as a barrier to degradation in the r direction.  We 
determined the velocity of the mesh at either end to be 2.172·10
-9 m/s.  At this velocity, the stent 
persisted 31.9 days. Page | 16  
 
Solver Parameters 
The algebraic equations were solved using the direct 
method,  not  the  iterative.    The  simulation  lasted 
2592000 seconds (30 days) with time steps at every 
86400 seconds (one day), allowing the solver to take 
free  time  steps  since  our  output  time  steps  are 
relatively large.  The relative tolerance of the solver 
was set to 0.01 and absolute tolerance of the solver 
was set to 0.0010.  This limits the size of the local 
error in each element in the Finite Element Method 
that the solver utilizes.  The variable in question is 
the concentration of drug in each element, making 
sure that the maximum error in any element does not 
exceed 0.0010. 
Three noded elements (2D triangles) were used in an unstructured mesh. To improve accuracy of 
the model, the mesh was unevenly distributed such that more elements were present at the tissue 
– stent interface (Fig. 2).  Since this is the area where the greatest amount of change is likely to 
be occurring, more elements at this location would improve the simulation. 
Mesh Convergence 
We performed mesh convergence by calculating the average concentration of drug in the tissue 
subdomain  at  the  end of  32 days by subdomain integration of the concentration divided by 
integrated volume using several meshes of varying number of elements, then plotting the average 
concentration in the tissue versus number of elements. 
 
Figure 9: Model mesh. Page | 17  
 
 
Figure 10: Average concentration of paclitaxel in tissue versus number of elements 
We noticed that the values continue to oscillate a little around an average of about 62.7nM, but 
the difference is very small. Thus we concluded that the mesh converges around 10880 elements. Page | 18  
 
Appendix C 
 
Figure 11: Concentration at center, 5 microns deep in the tissue at various initial loads. 
 
Figure 12: Concentration at center, 5 microns deep in the tissue at various initial loads.  Zoomed into last 2 days. 
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